Drug intelligence / Profile preview

DC-81

Development stage: Preclinical
Modality: Small Molecules

Overview

DC-81 is an **antitumor antibiotic** that acts as a potent inhibitor of nucleic acid synthesis. It recognizes and binds to specific sequences of DNA and can form labile covalent bonds with DNA, disrupting DNA function. This agent is primarily researched for its ability to interact with DNA, and is considered an experimental molecule with antitumor properties[2].

Other names: Antibiotic DC 81

Targets

DNA

Beyond the preview

Go deeper on DC-81.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC-81.

Explore the full profile